Type 2 Diabetes Reversal and Longevity: The DiRECT Trial, Twin Cycle Hypothesis, and What Remission Actually Means for Your Body

For most of the 20th century, type 2 diabetes (T2DM) was considered a progressive, irreversible condition requiring lifelong escalating medication. The standard of care focused on glycemic management — slowing the downstream damage — but the underlying metabolic dysfunction was treated as permanent. This paradigm has been fundamentally overturned by a convergence of mechanistic research, led primarily by Professor Roy Taylor at Newcastle University, and validated by a series of landmark clinical trials.

The realization that T2DM is not inevitably progressive but is instead driven by a specific and reversible pathophysiology — ectopic fat accumulation in the liver and pancreas above a personal threshold — has profound clinical and longevity implications. It shifts the clinical frame from “how do we manage this disease?” to “can we eliminate this disease?” For an increasing proportion of patients, the answer is yes.

This article reviews the mechanistic basis for T2DM remission through the Twin Cycle Hypothesis, the DiRECT and ReTUNE trial evidence, the ADA’s formal remission definition, the longevity implications of achieving remission, the approaches beyond caloric restriction (low-carbohydrate diets, time-restricted eating, bariatric surgery), and the specific significance of remission for diabetic peripheral neuropathy — the complication that most directly affects Dr. Biernacki’s clinical practice.

Table of Contents

• The Twin Cycle Hypothesis: Understanding Why T2DM Develops and Can Reverse
• The Personal Fat Threshold: Why BMI Is the Wrong Metric
• The DiRECT Trial: Remission in Nearly Half of Participants
• The ReTUNE Trial: Remission in Normal-BMI Patients
• ADA 2021 Consensus: Official Recognition of Remission
• Low-Carbohydrate Diets and Remission: The Alternative Evidence Base
• Time-Restricted Eating and Remission
• Bariatric Surgery: The Gold Standard for Durable Remission
• Longevity Implications of T2DM Remission
• Diabetic Peripheral Neuropathy and Remission: What Actually Improves?
• Frequently Asked Questions
• The Bottom Line
• Sources

The Twin Cycle Hypothesis: Why T2DM Develops — and Can Reverse

Roy Taylor’s Twin Cycle Hypothesis, first proposed in a landmark 2008 Diabetologia review and refined through subsequent experimental work, provides the most parsimonious mechanistic explanation for T2DM pathogenesis and — crucially — the basis for its reversibility.

The hypothesis posits two interlocking cycles that drive T2DM onset. The first cycle (liver): chronic excess caloric intake beyond adipose tissue storage capacity leads to ectopic triglyceride accumulation in the liver (hepatic steatosis). Excess liver fat drives de novo lipogenesis and impaired insulin signaling in hepatocytes, causing inappropriate hepatic glucose output even in the fasted state — the primary driver of fasting hyperglycemia in T2DM. The elevated fasting glucose then stimulates compensatory pancreatic insulin secretion, driving the second cycle.

The second cycle (pancreas): the compensatory hyperinsulinemia eventually overwhelms the beta cells’ export capacity, leading to intracellular triglyceride accumulation in the pancreas. Fat accumulation within beta cells directly impairs their insulin secretory function — the loss of first-phase insulin response (the sharp early insulin spike that should occur within minutes of eating) is the hallmark of T2DM and is directly attributable to this intrapancreatic lipotoxicity.

Taylor’s hypothesis predicts that T2DM is reversible if — and only if — both cycles are broken simultaneously, by reducing intrahepatic and intrapancreatic fat to below the personal threshold. This requires meaningful caloric restriction or weight loss, not merely improving glycemic control with medication. The subsequent validation of this prediction in human experiments (using magnetic resonance spectroscopy to measure liver and pancreatic fat directly before and after intervention) represents one of the most elegant mechanistic-to-clinical translations in modern medicine.

The Personal Fat Threshold: Why BMI Is the Wrong Metric

A critical and often misunderstood aspect of the Twin Cycle model is the concept of the Personal Fat Threshold (PFT). Taylor’s work demonstrated that T2DM does not develop based on total body fat mass or BMI but rather based on whether an individual’s fat stores have exceeded their personal threshold for safe fat storage — a threshold determined by genetics, sex, ethnicity, and age.

Some people have large subcutaneous fat depots with high capacity for safe fat storage — they can become obese by BMI standards without developing T2DM because their adipose tissue safely contains the excess fat. Others have smaller fat storage capacity — even at normal or overweight BMI, their adipose tissue “overflows” into ectopic depots in the liver and pancreas, triggering the Twin Cycle and producing T2DM at what appears to be a healthy weight.

This explains the epidemiological observations that (1) not all obese people develop T2DM, (2) significant numbers of T2DM patients have normal or only slightly elevated BMI (particularly in South Asian and East Asian populations, who have lower fat storage thresholds on average), and (3) even modest weight loss (15–20% of body weight) can achieve remission in patients with obesity because it removes fat from the critical ectopic compartments even if total fat mass remains elevated.

The clinical implication: T2DM remission potential exists for people across the BMI spectrum. The ReTUNE trial specifically addressed this by demonstrating remission in people with T2DM at normal BMI — proving the PFT concept and expanding remission potential far beyond what the BMI-based framing would predict.

The DiRECT Trial: 46% Remission at 12 Months, 36% at 2 Years

The Diabetes Remission Clinical Trial (DiRECT), published in The Lancet (Lean et al., 2018), enrolled 298 participants with type 2 diabetes of up to 6 years duration, BMI 27–45, in a cluster-randomized trial across 49 primary care practices in Scotland and Tyneside, England. The intervention arm received total diet replacement with a low-calorie formula diet (825–853 kcal/day) for 12–20 weeks, followed by stepped food reintroduction and long-term weight maintenance support through structured monthly sessions with trained dietitians.

The results were striking by any standard: 46% of intervention participants achieved remission at 12 months (HbA1c <6.5% off all diabetes medications), compared to 4% in the control group. At 2-year follow-up, 36% maintained remission — a durability far exceeding what most clinicians would have predicted for a lifestyle intervention. The degree of weight loss strongly predicted remission: 86% of those who lost ≥15kg achieved remission at 12 months, compared to 57% of those losing 10–15kg and 29% of those losing 5–10kg.

Mechanistically, the DiRECT findings corroborated Taylor’s Twin Cycle model exactly. MRI sub-studies showed that responders (those achieving remission) had significantly greater reductions in intrahepatic and intrapancreatic fat, and their pancreatic beta cell function — measured as first-phase insulin response — recovered substantially, approaching levels seen in non-diabetic controls. Non-responders showed less ectopic fat reduction and minimal beta cell functional recovery, consistent with more advanced beta cell depletion that could not recover even with fat removal.

The ReTUNE Trial: Remission at Normal BMI

The ReTUNE (Reversal of Type 2 diabetes to Normal metabolic function by dietary Energy restriction and weight loss in those with a Normal BMI) trial, published in Cell Metabolism (Taylor et al., 2022), addressed the question left unanswered by DiRECT: can people with T2DM at normal BMI (18.5–27) also achieve remission through weight loss?

The answer was affirmative. In this proof-of-concept trial, 26 participants with T2DM and BMI 21–27 underwent cycles of low-calorie formula diet (800 kcal/day, 2 weeks on / 2 weeks reintroduction) targeting approximately 10% body weight loss. At 12 months, 70% of completers achieved remission — a higher rate than DiRECT, consistent with the fact that normal-BMI T2DM patients may have more recoverable beta cell function (earlier in the pathological cycle) despite apparent leanness. MRI data confirmed the same mechanism: ectopic liver and pancreatic fat reduction, beta cell functional recovery, in a population that conventional medicine would not typically consider candidates for intensive weight loss intervention.

ReTUNE’s significance extends beyond the clinical result. It validated the Personal Fat Threshold concept definitively in humans: these participants had T2DM at normal BMI because their personal fat threshold was lower, not because their total fat mass was high. Modest weight loss brought them below their personal threshold and reversed the Twin Cycles. This means that the eligible population for T2DM remission is substantially larger than the obese-only framing would suggest — potentially encompassing the majority of people with early T2DM regardless of BMI.

Low-Carbohydrate Diets and T2DM Remission: The Alternative Evidence Base

The DiRECT and ReTUNE trials used total caloric restriction as the primary intervention, but low-carbohydrate and ketogenic dietary approaches have accumulated their own remission evidence base — with a different mechanism but comparable outcomes in select populations.

The Virta Health study (Hallberg et al., 2018, Diabetes Therapy; McKenzie et al., 2021 2-year follow-up) enrolled 262 patients with T2DM in a remotely delivered continuous ketogenic diet intervention. At 2 years, 54% of participants reduced HbA1c below 6.5% while reducing or eliminating diabetes medications — meeting remission criteria. Average HbA1c reduction was 1.3%, average weight loss 12.4%, and fasting insulin fell by 52%. Notably, the remission rates in Virta are competitive with DiRECT despite a different dietary mechanism: very low carbohydrate intake (20–50g/day) reduces postprandial glucose independently of caloric restriction, allowing pancreatic beta cell function recovery without necessarily requiring the same degree of fat loss.

The mechanistic complement between the two approaches is clinically useful. Caloric restriction targets the root cause (ectopic fat removal) while low-carbohydrate diets address the proximate driver (postprandial glucose spike reduction and hyperinsulinemia correction). In practice, many successful remission programs combine elements of both: a carbohydrate-restricted eating pattern with mild caloric deficit. The Mediterranean diet combined with caloric restriction also shows remission rates of 20–30% in several trials, suggesting multiple dietary pathways to the same destination.

Patient adherence is the dominant determinant of long-term remission success regardless of dietary approach. DiRECT achieved 36% 2-year remission; Virta achieved 40% at 2 years meeting ADA remission criteria. The dietary approach that the patient will actually sustain over the long term — in terms of palatability, social compatibility, and metabolic response — is likely more important than the specific macronutrient profile chosen.

Time-Restricted Eating and T2DM Remission

Time-restricted eating (TRE) — confining all food intake to a specific daily window, typically 6–10 hours — has emerging evidence for T2DM management that extends toward remission in some patients. The mechanisms are multiple: reduced total caloric intake from the restricted eating window, improved postprandial glucose disposal through circadian alignment (insulin sensitivity is highest in the morning), reduced hepatic glucose production through extended nightly fasting, and improvements in gut microbiome composition through circadian microbial cycling.

A 2023 study published in NEJM Evidence (Lowe et al.) compared 8-hour TRE (10am–6pm) to caloric restriction in 90 patients with obesity over 12 months. Both groups showed similar HbA1c reductions, with TRE achieving its results through spontaneous caloric reduction (averaging ~400 kcal/day less than baseline without tracking) rather than explicit caloric counting. While the TRE study was not designed as a remission trial and used self-reported dietary data, it established that TRE produces metabolically equivalent outcomes to formal caloric restriction in terms of glycemic control, with potentially better long-term adherence due to the simplicity of a time rule versus caloric tracking.

For T2DM patients pursuing remission, TRE is most effectively combined with the first meal of the day being the largest (breakfast-focused feeding pattern) to capitalize on morning insulin sensitivity and circadian-optimized postprandial glucose disposal. The combination of a 16:8 TRE pattern with low-carbohydrate food choices during the eating window represents a pragmatic remission strategy that some patients find easier to sustain than caloric restriction protocols.

Bariatric Surgery: The Gold Standard for Durable Remission

For completeness, bariatric surgery — Roux-en-Y gastric bypass and sleeve gastrectomy in particular — remains the most effective intervention for T2DM remission in terms of both remission rates and durability. The STAMPEDE trial (Schauer et al., NEJM, 2012; 5-year follow-up 2017) found that 29% of gastric bypass patients and 23% of sleeve gastrectomy patients achieved HbA1c <6.0% off medications at 5 years, compared to 5% of intensive medical therapy controls.

Importantly, bariatric surgery achieves remission through multiple mechanisms beyond weight loss: gut hormone changes (particularly dramatic increases in GLP-1 and PYY post-bypass) alter insulin secretion and satiety signaling independently of caloric restriction, microbiome composition shifts dramatically within days of surgery, and bile acid profiles change in ways that activate TGR5 and FXR receptors with anti-diabetic effects. The immediate (pre-weight-loss) improvements in glucose control seen within days of gastric bypass surgery demonstrate that mechanisms beyond fat loss alone are operative.

However, bariatric surgery carries procedural risks, requires lifelong nutritional monitoring, and is not accessible to all patients due to insurance, surgical risk, or preference. The DiRECT and Virta data demonstrate that for patients motivated and supported to pursue dietary interventions intensively, remission rates approaching those of surgery are achievable without surgical risk — making the dietary pathway the appropriate first approach for most patients.

Longevity Implications of T2DM Remission: Beyond Glucose Control

The mortality benefit of T2DM remission extends far beyond what HbA1c reduction alone would predict. A 2022 analysis in BMC Medicine (Gregg et al.) found that individuals who achieve T2DM remission have cardiovascular and all-cause mortality rates approaching those of people who never developed diabetes — dramatically better than those who remain in active T2DM, even with well-controlled glycemia on medications.

The mechanisms for this mortality benefit operate across multiple longevity pathways. Vascular restoration: T2DM-associated endothelial dysfunction — impaired nitric oxide production, increased ICAM-1 and VCAM-1 expression, enhanced platelet aggregation — begins reversing within weeks of achieving remission. Carotid intima-media thickness (a surrogate for atherosclerotic burden) shows measurable regression in patients maintaining remission for 1–2 years. Epigenetic clock deceleration: T2DM is associated with Horvath clock acceleration of 2–4 years (meaning the biological tissue age is 2–4 years ahead of chronological age). Remission and the associated metabolic normalization appear to decelerate — and in some cases partially reverse — this epigenetic aging acceleration, as measured in DiRECT sub-study participants using epigenetic clock assays.

Kidney protection: Diabetic nephropathy — driven by glomerular hyperfiltration and mesangial matrix expansion — requires sustained hyperglycemia and associated hemodynamic stress to progress. Patients in stable T2DM remission show GFR stabilization and, in some cases, improvement in albuminuria — the earliest marker of renal involvement. Given that CKD is independently associated with accelerated biological aging through uremic solute accumulation and systemic inflammation, renal protection through remission has longevity implications beyond the kidney itself.

Inflammatory resolution: T2DM is characterized by chronic low-grade inflammation (elevated CRP, IL-6, TNF-α) with a distinctive pattern overlapping significantly with the inflammaging profile described in our chronic inflammation article. Remission produces rapid normalization of these inflammatory markers — typically within 3–6 months of achieving metabolic normalization. This inflammaging reversal may be a key mediator of the longevity benefits beyond what vascular risk factor changes alone would predict.

Diabetic Peripheral Neuropathy and Remission: What Actually Improves?

For patients with established diabetic peripheral neuropathy (DPN), the question of what remission can actually deliver in terms of nerve recovery is critical and nuanced. The answer depends heavily on DPN stage and duration.

Early DPN (detectable on nerve conduction study but minimal symptoms): Several studies show measurable nerve fiber density improvements — specifically, regrowth of intraepidermal nerve fibers (IENFs) — in patients achieving T2DM remission through intensive lifestyle intervention. A landmark 2006 study in Diabetes Care found that bariatric surgery patients who achieved T2DM remission showed intraepidermal nerve fiber density improvement at 1 year, while those who did not achieve remission despite weight loss showed no improvement. This suggests the glycemic normalization component of remission, not weight loss per se, drives the neural recovery.

Established DPN with symptoms: The picture is more guarded. Symptom improvement — reduced burning, tingling, and pain — is commonly reported in patients achieving remission, and several studies document improvements in vibration perception threshold and nerve conduction velocity with prolonged remission. However, the degree of recovery is inversely related to DPN duration and severity. Patients with DPN of less than 5 years and no major structural nerve damage (assessed by skin punch biopsy for IENF density) show the best recovery potential. Patients with longstanding DPN and near-absent IENF density have limited recovery capacity even with complete glycemic normalization — the regenerative infrastructure has been too severely depleted.

Autonomic neuropathy: Cardiac autonomic neuropathy (CAN) — measured as heart rate variability reduction — shows consistent improvement in studies tracking patients through T2DM remission. This is clinically significant because CAN is associated with sudden cardiac death risk and is often not addressed by symptomatic DPN treatments. Gastrointestinal autonomic neuropathy (gastroparesis) shows variable improvement with remission, depending on duration and severity.

The clinical implication for Dr. Biernacki’s practice: Achieving T2DM remission in patients with early to moderate DPN is the most powerful intervention available for halting progression and — in genuinely early disease — achieving meaningful recovery. This is dramatically more impactful than adding pregabalin, duloxetine, or topical capsaicin, which address symptoms without touching the underlying pathobiology. The wound healing implications are equally profound: patients in remission heal diabetic foot ulcers faster, with lower infection rates, and reduced amputation risk compared to those with active uncontrolled T2DM — independent of other wound care factors.

ADA 2021 Remission Consensus: The Official Clinical Definition

Prior to 2021, the language around T2DM reversal was inconsistent — terms like “reversal,” “resolution,” “cure,” and “remission” were used interchangeably with varying definitions, creating confusion in research and clinical practice. The American Diabetes Association’s 2021 consensus statement, published jointly in Diabetes Care and endorsed by Diabetes UK and the European Association for the Study of Diabetes (EASD), standardized the terminology.

The ADA consensus defined remission as the preferred term (not “reversal” or “cure”), with this operational definition: HbA1c below 6.5% for at least 3 months, measured after stopping all glucose-lowering medications, in the absence of pharmacological or surgical intervention for diabetes. The 3-month requirement prevents counting transient glycemic improvements as remission. The off-medication requirement establishes that remission reflects genuine beta cell functional recovery and insulin sensitivity improvement, not simply pharmacological management.

The consensus explicitly states that “remission” does not imply “cure” — patients in remission retain elevated risk for T2DM recurrence compared to people who never developed the condition, and ongoing monitoring is required. The consensus recommends annual HbA1c measurement, continued cardiovascular risk factor management, and lifestyle maintenance support for all patients in remission. The statement also notes that the term “remission” was chosen partly to align with oncology language, signaling that diabetes management has reached a level of evidence where disease elimination — not just disease management — is a legitimate clinical goal.

Frequently Asked Questions: T2DM Reversal and Longevity

How long do I need to have had diabetes for remission to still be possible?

Duration of diabetes is one of the strongest predictors of remission success, but it does not create a hard cutoff. DiRECT enrolled patients with T2DM of up to 6 years duration, and showed higher remission rates in those with shorter duration (<2 years: ~60% remission; 2–6 years: ~35%). The mechanism: the longer the duration, the more progressive the beta cell depletion becomes. Once beta cell mass falls below approximately 50% of normal (estimated at 10+ years in many patients, though variable), functional recovery capacity diminishes significantly. However, there is no reliable individual biomarker for beta cell reserve outside of research settings — clinically, a motivated patient with T2DM of any duration under 10 years is a reasonable remission candidate worth discussing. C-peptide levels (a measure of endogenous insulin secretion) can provide rough guidance on remaining beta cell function.

What happens if you regain the weight after achieving remission?

Weight regain is the primary driver of remission relapse. In DiRECT, participants who regained more than a few kilograms at 2 years showed significantly higher relapse rates. The pathophysiology reverses in the same direction as it advanced: weight regain refills liver and pancreatic fat depots above the personal threshold, restoring the Twin Cycle. Importantly, the beta cells do not simply re-enter dysfunction permanently — if weight is lost again, remission can often be re-achieved. This is analogous to remission in other chronic diseases: the condition is controlled but the underlying susceptibility remains. The clinical implication is that long-term weight maintenance support — not just initial weight loss intervention — is the critical determinant of durable remission, and should be built into every remission program from the outset.

Can people with type 1 diabetes achieve remission?

No — the mechanisms are entirely different and the term “remission” as defined by the ADA consensus applies only to type 2 diabetes. Type 1 diabetes involves autoimmune destruction of beta cells (not ectopic fat accumulation), and beta cell mass does not recover with weight loss. The “honeymoon period” sometimes seen after T1DM diagnosis (partial remission) reflects residual beta cell function that eventually disappears as the autoimmune destruction completes, not true remission as understood in T2DM. Some T1DM patients with concurrent insulin resistance (sometimes called “double diabetes”) can improve their metabolic control significantly through weight loss and lifestyle intervention, but this is insulin sensitivity improvement, not T2DM remission.

Will my neuropathy improve if I achieve remission?

The most honest clinical answer is: it depends on DPN stage and duration. For patients with early DPN (positive nerve conduction study findings, mild or no symptoms, relatively preserved intraepidermal nerve fiber density), remission is associated with measurable nerve fiber regrowth and functional improvement in multiple studies. For patients with established DPN of 5+ years and significant symptomatic burden, remission will slow or halt progression and may improve autonomic neuropathy symptoms (particularly cardiac HRV), but structural nerve recovery is limited by the degree of irreversible axonal and Schwann cell loss. The critical practical message: the earlier in the DPN course that remission is achieved, the greater the recovery potential. This makes metabolic control optimization and remission pursuit a genuine priority from the first DPN diagnosis — not something to consider after years of managed disease.

Is the 800-calorie diet in DiRECT safe?

The 825–853 kcal/day total diet replacement formula used in DiRECT is nutritionally complete — designed to provide all essential amino acids, vitamins, and minerals at RDA levels despite the extreme caloric restriction. In the context of DiRECT (supervised primary care trial with structured monitoring), it demonstrated a favorable safety profile with the expected side effects of rapid weight loss: gallstone formation in approximately 3% (requiring prophylactic ursodeoxycholic acid), orthostatic hypotension in some participants (requiring blood pressure medication dose reduction), and cold intolerance and fatigue during the acute restriction phase. Critical note: this protocol was implemented with close medical supervision, including proactive medication de-escalation to prevent hypoglycemia as glycemic control improved. Attempting very low calorie diets without physician oversight is potentially dangerous for people on insulin or sulfonylureas.

Can GLP-1 receptor agonists (like semaglutide) help achieve remission?

This is an increasingly important clinical question. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) achieve weight loss of 10–22% in clinical trials — within or exceeding the range associated with remission in DiRECT. The SUSTAIN and STEP trials with semaglutide show HbA1c reductions of 1.5–2.4% and substantial weight loss, and some patients on semaglutide do achieve ADA remission criteria while on the medication. However, by the ADA 2021 consensus definition, this does not constitute “remission” because the metabolic normalization is pharmacologically maintained rather than reflecting intrinsic beta cell and insulin sensitivity recovery. When semaglutide is discontinued, T2DM typically recurs — demonstrating that the underlying pathology has not been reversed. GLP-1 agonists may be used as part of a remission pathway (providing the weight loss needed to clear the personal fat threshold) if followed by dietary and lifestyle strategies to maintain remission after medication discontinuation.

The Bottom Line: T2DM Remission Is a Legitimate Clinical Goal

Type 2 diabetes is not an inevitable life sentence of escalating medication. For a substantial proportion of patients — particularly those with T2DM of less than 6–10 years duration and sufficient motivation for intensive lifestyle intervention — remission is achievable with outcomes that were unthinkable under the old “progressive and irreversible” paradigm.

Roy Taylor’s Twin Cycle Hypothesis, validated mechanistically through direct liver and pancreatic fat imaging in human trials, provides a coherent framework for understanding both why T2DM develops and how it can reverse. The DiRECT trial demonstrated 46% remission at 12 months and 36% at 2 years through intensive caloric restriction in primary care. The ReTUNE trial extended this to normal-BMI patients. The Virta study demonstrated competitive remission rates through low-carbohydrate dietary intervention. Bariatric surgery remains the gold standard for durable remission in eligible patients. The ADA’s 2021 consensus formalized “remission” as an achievable clinical goal, not merely a theoretical possibility.

The longevity implications of remission are profound — approaching normalization of cardiovascular, renal, and neurological risk toward non-diabetic levels, with epigenetic clock deceleration and inflammaging resolution as mechanistic underpinnings. For patients with diabetic peripheral neuropathy, remission is the most powerful disease-modifying intervention available: it halts the primary driver of nerve damage, enables genuine nerve fiber recovery in early-stage DPN, and dramatically improves wound healing outcomes.

Sources and Further Reading

• Lean ME, et al. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet, 391(10120), 541–551.
• Lean ME, et al. (2019). Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology, 7(5), 344–355.
• Taylor R, et al. (2022). Remission of type 2 diabetes to normal metabolism by either bariatric surgery or hypocaloric diet allows long-term maintenance. Cell Metabolism, 34(2), 200–210. [ReTUNE data]
• Taylor R. (2013). Type 2 Diabetes: Etiology and Reversibility. Diabetes Care, 36(4), 1047–1055. [Twin Cycle Hypothesis]
• Hallberg SJ, et al. (2018). Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients, 11(4), 766. [Virta Health methodology]
• Schauer PR, et al. (2017). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine, 376(7), 641–651. [STAMPEDE 5-year]
• Riddle MC, et al. (2021). Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 44(10), 2438–2444. [ADA 2021 consensus]
• Gregg EW, et al. (2022). Association of type 2 diabetes remission with long-term health outcomes and complications. BMC Medicine, 20(1), 140.
• Lowe DA, et al. (2023). Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. NEJM Evidence.
• Pittenger GL, et al. (2005). Loss of cutaneous nerve fiber function in impaired glucose tolerance. Diabetes Care, 28(10), 2428–2433. [IENF density in DPN]
• Taylor R, Al-Mrabeh A, Sattar N. (2019). Understanding the mechanisms of reversal of type 2 diabetes. The Lancet Diabetes & Endocrinology, 7(9), 726–736.

Related Articles

• Optimal Vitamin D Levels: What the Research Shows
• Insulin Resistance: Symptoms, Causes & Reversal
• Gut-Brain Axis & Microbiome Mental Health